REVLIMID
Drug
Celgene Corporation
Total Payments
$1.5M
Transactions
78
Doctors
2
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $613,334 | 56 | 0 |
| 2023 | $891,975 | 12 | 2 |
| 2019 | $42,835 | 10 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.5M | 78 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Randomized Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone to High-Dose Treatment With ASCT in the Initial Management of Myeloma in Patients up to 65 Years of Age | Celgene Corporation | $363,360 | 0 |
| 1401: Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell /Myeloma Fusions | Celgene Corporation | $255,000 | 0 |
| A Phase II Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects with Follicular Lymphoma | Celgene Corporation | $253,511 | 0 |
| An international working group for the integration of molecular data in CMML | Celgene Corporation | $116,819 | 0 |
| Lenalidomide and Dexamethasone (Ld) versus Clarithromycin [Biaxin] / Lenalidomide [Revlimid] / Dexamethasone (BiRd) as initial therapy in Multiple Myeloma. | Celgene Corporation | $91,734 | 0 |
| A Phase I/II Trial of CHOEP Chemotherapy plus Lenalidomide as Front Line Therapy for Patients with Stage II, III and IV Peripheral T-Cell Non-Hodgkins Lymphoma | Celgene Corporation | $75,974 | 0 |
| Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma: A Phase II Study | Celgene Corporation | $71,871 | 0 |
| Connect MM- The Multiple Myeloma Disease Registry | Celgene Corporation | $64,853 | 0 |
| Combination of Lenalidomide and Obinutuzumab in Patients with Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Celgene Corporation | $48,563 | 0 |
| Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy | Celgene Corporation | $44,000 | 0 |
| An Open-Label, Dose-Escalation, Phase 1-2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination with Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment | Takeda Pharmaceuticals U.S.A., Inc. | $42,835 | 0 |
| A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma | Celgene Corporation | $42,741 | 0 |
| Phase II study of bendamustine and rituximab induction chemoimmunotherapy followed by maintenance rituximab (Rituxan) and lenalidomide (Revlimid) in untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) | Celgene Corporation | $41,271 | 0 |
| Phase I/II Study of Lenalidomide and Ofatumumab for the treatment of relapsed or refractory Non-Hodgkins Lymphoma. | Celgene Corporation | $19,787 | 0 |
| Connect MM- The Multiple Myeloma Disease Registry | E.R. Squibb & Sons, L.L.C. | $9,375 | 0 |
| Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide-R-ICE (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Celgene Corporation | $3,750 | 0 |
| Connect MM The Multiple Myeloma Disease Registry | Celgene Corporation | $2,700 | 2 |
Ad
Manufacturing Companies
- Celgene Corporation $1.5M
- Takeda Pharmaceuticals U.S.A., Inc. $42,835
- E.R. Squibb & Sons, L.L.C. $9,375
Product Information
- Type Drug
- Total Payments $1.5M
- Total Doctors 2
- Transactions 78
About REVLIMID
REVLIMID is a drug associated with $1.5M in payments to 2 healthcare providers, recorded across 78 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2019 to 2024. In 2024, $613,334 was paid across 56 transactions to 0 doctors.
The most common payment nature for REVLIMID is "Unspecified" ($1.5M, 100.0% of total).
REVLIMID is associated with 17 research studies, including "Randomized Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone to High-Dose Treatment With ASCT in the Initial Management of Myeloma in Patients up to 65 Years of Age" ($363,360).